- Home
- XGN vs TLSI Comparison
XGN vs TLSI Comparison
Compare XGN & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- TLSI
- Stock Information
- Founded
- XGN 2002
- TLSI 2010
- Country
- XGN United States
- TLSI United States
- Employees
- XGN N/A
- TLSI N/A
- Industry
- XGN Medical Specialities
- TLSI Medical Specialities
- Sector
- XGN Health Care
- TLSI Health Care
- Exchange
- XGN Nasdaq
- TLSI Nasdaq
- Market Cap
- XGN 210.4M
- TLSI 244.3M
- IPO Year
- XGN 2019
- TLSI N/A
- Fundamental
- Price
- XGN $11.04
- TLSI $4.59
- Analyst Decision
- XGN Strong Buy
- TLSI Strong Buy
- Analyst Count
- XGN 5
- TLSI 4
- Target Price
- XGN $12.40
- TLSI $11.13
- AVG Volume (30 Days)
- XGN 258.8K
- TLSI 142.6K
- Earning Date
- XGN 11-11-2025
- TLSI 11-13-2025
- Dividend Yield
- XGN N/A
- TLSI N/A
- EPS Growth
- XGN N/A
- TLSI N/A
- EPS
- XGN N/A
- TLSI N/A
- Revenue
- XGN $58,862,000.00
- TLSI $35,990,000.00
- Revenue This Year
- XGN $22.28
- TLSI $56.71
- Revenue Next Year
- XGN $14.03
- TLSI $52.25
- P/E Ratio
- XGN N/A
- TLSI N/A
- Revenue Growth
- XGN 3.89
- TLSI 45.50
- 52 Week Low
- XGN $2.38
- TLSI $3.42
- 52 Week High
- XGN $11.28
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- XGN 64.51
- TLSI 46.03
- Support Level
- XGN $10.63
- TLSI $4.42
- Resistance Level
- XGN $11.28
- TLSI $4.67
- Average True Range (ATR)
- XGN 0.38
- TLSI 0.26
- MACD
- XGN -0.00
- TLSI -0.04
- Stochastic Oscillator
- XGN 80.41
- TLSI 47.13
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.